As Francis Chaouloff, a researcher at the University of Bordeaux in France and lead author of the genetically modified mouse study, pointed out in an e-mail, rodents, although fine models for studying endocannabinoid action, "do not fill questionnaires to express their feelings related to running," and runners' high is a subjective human experience.
Imatinib (NCT01140360) and sorafenib (NCT00727233) are two trials which have been recently undertaken based on mouse modeling, but these studies point out the complexity of the transition from mouse models to human care.
Expert review was performed on data outputs of the chronic/cancer rat or mouse studies, including all of the end points captured in the data tables of this publication.
The mouse studies can be used as a starting point to look for similar effects in humans.
The hopes they raise rest solely on mouse studies.
This theory emerged from those mouse studies at the Salk Institute.
When the model for the mouse study was first designed, the end point was set to be the day when the mice began to produce ascites, or acute gain of weight due to tumour growth, for reasons of ethical origin.
Regarding mice studies, it should be pointed out that comparative genomics research demonstrated that mouse and human IL-6 share only 42% aminoacid sequence identity [ 21]; hence, in this particular case extrapolation of mice findings to humans requires extreme caution.
While it was thought that the effects of hyperthyroidism occurred at the level of myofibers (Simonides and van Hardeveld, 2008), the reduced expression of Pax7 and increased apoptosis in hyperthyroid muscle in mice characterized in this study point to a failure at stem cell level, which may well occur also in humans.
Maria was a mouse studying to be a rat.
